1. The combined composition in a hard capsule containing two or more pharmaceutically active ingredients, where each pharmaceutically active ingredient is contained in a multicomponent spheroidal tablet (MKST), having a diameter in the range from 1 to 4 mm, and from 4 to 40 MKST for each pharmaceutically active ingredient enclosed in a hard capsule. 2. The combined composition in a hard capsule according to claim 1, wherein the ratio of diameter to thickness for each MKST is in the range from 1: 0.7 to 1: 1.3.3. The combined composition in a hard capsule according to claim 1, wherein the diameter of each MKST is less than or equal to 1/2 of the inner diameter of the hard capsule. The combined composition in a hard capsule according to claim 1, wherein the ratio of wall thickness to cylinder height for each MKST is in the range from 1: 0.3 to 1: 0.9.5. The combined composition in a hard capsule according to claim 4, wherein the ratio of wall thickness to cylinder height is in the range from 1: 0.5 to 1: 0.8.6. The combined composition in a hard capsule according to claim 1, wherein the hard capsule is hard capsule No. 0, hard capsule No. 1, hard capsule No. 2, hard capsule No. 3 or hard capsule No. 4.7. The combined composition in a hard capsule according to claim 1, wherein each pharmaceutically active ingredient is selected from the group consisting of levocetirizine, montelukast, ambroxol, levodropropisin, losartan, ibersartan, amlodipine, rosuvastatin, atorvastatin, aspirin, clopidogrenazole, epacelazole, epacelazeprase, aceclase, aceclose, and their pharmaceutically acceptable salts. 8. The combined composition in a hard capsule according to claim 1, wherein each MKST contains a pharmaceutically acceptable additive. The combined composition in a hard capsule according to claim 8, wherein the pharmaceutically acceptable additive is selected from the group consisting of1. Комбинированный состав в твердой капсуле, содержащий два или более фармацевтически активных и
